Establishment Labs Files 8-K

TL;DR

ESTA filed an 8-K on Jan 16 for an event on Jan 15. Reg FD disclosure.

AI Summary

Establishment Labs Holdings Inc. filed an 8-K on January 16, 2025, reporting an event on January 15, 2025. The filing is categorized under Regulation FD Disclosure. The company is incorporated in the British Virgin Islands and its principal executive offices are located in Alajuela, Costa Rica.

Why It Matters

This 8-K filing indicates a regulatory disclosure event for Establishment Labs Holdings Inc., which could contain important updates for investors regarding company communications or events.

Risk Assessment

Risk Level: low — This is a standard regulatory filing (8-K) and does not appear to contain immediate material financial or operational news.

Key Players & Entities

• ESTABLISHMENT LABS HOLDINGS INC. (company) — Registrant
• January 15, 2025 (date) — Date of earliest event reported
• January 16, 2025 (date) — Date of Report
• Alajuela, Costa Rica (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $205 million — . Guidance for 2025 includes revenue of $205 million to $210 million, including $170 million
• $210 m — 025 includes revenue of $205 million to $210 million, including $170 million to $175 m
• $170 million — $205 million to $210 million, including $170 million to $175 million in international sales
• $175 million — $210 million, including $170 million to $175 million in international sales and $35 million
• $35 million — $175 million in international sales and $35 million in sales in the United States. The Comp

Filing Documents

• esta-20250115.htm (8-K) — 28KB
• 0001688757-25-000008.txt ( ) — 151KB
• esta-20250115.xsd (EX-101.SCH) — 2KB
• esta-20250115_lab.xml (EX-101.LAB) — 22KB
• esta-20250115_pre.xml (EX-101.PRE) — 13KB
• esta-20250115_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. In a presentation at the J.P. Morgan Healthcare Conference on January 15, 2025, Establishment Labs (the "Company") provided updated financial guidance. Guidance for 2025 includes revenue of $205 million to $210 million, including $170 million to $175 million in international sales and $35 million in sales in the United States. The Company also expects to achieve positive adjusted EBITDA in 2025 and positive cash flow in 2026. The information in this report is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein. Special Note Regarding Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended or the Exchange Act. These estimates should not be viewed as a substitute for our full interim or annual financial statements prepared in accordance with U.S. generally accepted accounting principles. Accordingly, you should not place undue reliance on this preliminary data. The preliminary financial data has been prepared by, and is the responsibility of, our management. Marcum LLP, our independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to the accompanying preliminary financial data. Accordingly, Marcum LLP does not express an opinion or any other form of assurance with respect thereto.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ESTABLISHMENT LABS HOLDINGS INC. Dated: January 16, 2025 By: /s/ Rajbir S. Denhoy Name: Rajbir S. Denhoy Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR